Publications by authors named "H Kim-Lee"
Recent advances in mass transfer technology are expected to bring next-generation micro light-emitting diodes (µLED) displays into reality, although reliable integration of the active-matrix backplane with the transferred µLEDs remains as a challenge. Here, the µLED display technology is innovated by demonstrating pixel circuit-integrated micro-LEDs (PIMLEDs) and integrating them onto a transparent glass substrate. The PIMLED comprises of low-temperature poly-silicon transistors and GaN µLED.
View Article and Find Full Text PDFBackground & Aims: Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by excessive circulating toxic lipids, hepatic steatosis, and liver inflammation. Monocyte adhesion to liver sinusoidal endothelial cells (LSECs) and transendothelial migration (TEM) are crucial in the inflammatory process. Under lipotoxic stress, LSECs develop a proinflammatory phenotype known as endotheliopathy.
View Article and Find Full Text PDFArticle Synopsis
- This study explores how regulatory T cells (Tregs) behave in inflammatory bowel diseases like Crohn's disease, focusing on their metabolic processes that impact gut homeostasis.
- Researchers used various advanced techniques (like electron microscopy and mass cytometry) to analyze Tregs' cellular structures and functions in humans and murine models of colitis.
- Key findings show that inhibiting a specific protein (VDAC1) disrupts Treg metabolism and increases sensitivity to inflammation, while manipulating metabolic pathways can restore proper Treg function and potentially inform new therapeutic strategies for inflammatory diseases.
Article Synopsis
- - NASH (Non-Alcoholic Steatohepatitis) is a severe form of NAFLD (Non-Alcoholic Fatty Liver Disease) linked to liver damage, inflammation, and fibrosis, with ROCK1 protein being implicated in liver injury responses to high-fat diets.
- - Research showed elevated ROCK1 levels in patients and mice with NASH; knocking out ROCK1 in liver cells reduced liver damage and inflammation, indicating its critical role in NASH progression.
- - Administering a new ROCK inhibitor (ROCKi) improved liver health in mice with established NASH, suggesting that targeting ROCK1 may lead to effective treatments for human NASH.